While it has been thought that cytokines (secreted signalling molecules) such as interleukin-4 or interleukin-13 have a critical role in onset and development of clinical asthma for some 20 years, confirmatory evidence has until now been lacking.
Dr Malinda Longphre, Aerovance Inc, Berkeley, California, USA and colleagues did two separate phase two clinical trials, in which patients with asthma were given pitrakinra. In study one, 12 patients were given 25mg pitrakinra by subcutaneous injection once daily, while a further twelve were given placebo. In the second study, 16 patients received either 60mg pitrakinra twice daily by nebulisation, while a further 16 were given placebo. The patients in each study inhaled allergens before and four weeks after treatment (known as ‘allergen challenge’, which induces an asthma attack).
Allergen inhalation causes an allergic reaction in the lungs which reduces their capacity to expel air. The primary endpoint for study one was maximum percentage decrease in forced expiratory volume (FEV1)** in one second over 4-10 hours after allergen challenge, whereas in study two it was average percentage decrease in FEV1 over 4-10 hours after allergen challenge. Smaller decreases in FEV1 during the asthma attack for the pitrakinra group versus placebo would mean that the allergic response had been decreased by pitrakinra.
The researchers found that in study one, the maximum percentage decrease in FEV1 was 17.1% in the pitrakinra group and 23.1% in the placebo group – a relative difference of 26%. In study two, the average percentage decrease in FEV1 was 4.4% in the pitrakinra group compared with 15.9% in the placebo group – (more than 3 and half times less in the pitrakinra group).
The authors conclude: “The effects of pitrakinra on late phase asthmatic response are promising when compared with similar studies with other successful anti-inflammatory asthma therapies…..whether the effect is due to inhibition of interleukin-13 alone, or both interleukin-13 an interleukin-4, is not yet known. Future studies of this drug, as well as molecules that specifically inhibit interleukin-13, in asthmatic individuals of all levels of severity over longer periods of time are clearly warranted.”
In an accompanying Comment, Dr Patrick Holt and Dr Peter Sly, Telethon Institute for Child Health Research, University of Western Australia, Subiaco, Western Australia, Australia, say: “These latest findings with pitrakinra are exciting and novel, and will breathe new life into the debate surrounding the role of the Th2-cytokine cascade in asthma pathogenesis and how best to design drugs to attenuate their effects.”
Tony Kirby | alfa
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences